MCID: ATS008
MIFTS: 34

Autosomal Dominant Disease malady

Category: Genetic diseases (common)

Aliases & Classifications for Autosomal Dominant Disease

About this section

Aliases & Descriptions for Autosomal Dominant Disease:

Name: Autosomal Dominant Disease 10 12

Classifications:



External Ids:

Disease Ontology10 DOID:0050736

Summaries for Autosomal Dominant Disease

About this section
Disease Ontology:10 An autosomal genetic disease that is characterized by the presence of one disease-associated mutation of a gene which is sufficient to cause the disease.

MalaCards based summary: Autosomal Dominant Disease is related to doyne honeycomb degeneration of retina and beare-stevenson cutis gyrata syndrome. An important gene associated with Autosomal Dominant Disease is ALX4 (ALX Homeobox 4), and among its related pathways are Glypican 3 network and DNA damage_Role of Brca1 and Brca2 in DNA repair. Affiliated tissues include kidney, liver and bone, and related mouse phenotypes are hearing/vestibular/ear and respiratory system.

Related Diseases for Autosomal Dominant Disease

About this section

Diseases related to Autosomal Dominant Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 118)
idRelated DiseaseScoreTop Affiliating Genes
1doyne honeycomb degeneration of retina30.7MLH1, MSH2, MSH6, PMS2
2beare-stevenson cutis gyrata syndrome30.5FGFR2, FGFR3, MSX2
3polycystic kidney disease, adult type i11.3
4polycystic kidney disease 211.2
5chorioretinitis10.5MLH1, MSH2
6chondroblastoma10.5MLH1, MSH2
7atypical mole syndrome10.5MSH2, MSH6
8craniosynostosis 510.5ALX4, MSX2
9allergic contact dermatitis10.5MLH1, MSH2, MSH6
10small non-cleaved cell lymphoma10.5MLH1, MSH2, MSH6
11cardiomyopathy, hypertrophic, 410.5ALX4, MSX2
12hereditary renal cell carcinoma10.5MLH1, MSH2, PAX3
13neurofibromatosis, familial spinal10.5MLH1, MSH6, PMS2
14leukemoid reaction10.5MLH1, MSH2, MSH6
15adenomyoma of uterine corpus10.5MLH1, MSH2
16frontonasal dysplasia 210.5ALX4, MSX2
17plagiocephaly and x-linked mental retardation10.5FGFR2, FGFR3
18tracheal lymphoma10.5MLH1, MSH2, MSH6
19pelizaeus-merzbacher-like disease due to gjc2 mutation10.5PTCH1, SHH
20alobar holoprosencephaly10.5PTCH1, SHH
21flna-related periventricular nodular heterotopia10.5FGFR2, FGFR3
22colon adenoma10.4MLH1, MSH2, MSH6, PMS2
23hereditary congenital ptosis10.4MLH1, MSH2, MSH6, PMS2
24vascular hemostatic disease10.4MLH1, MSH2, MSH6, PMS2
25muir-torre syndrome10.4MLH1, MSH2, MSH6, PMS2
26spasticity-intellectual disability-x-linked epilepsy syndrome10.4PTCH1, SHH
27x-linked dominant intellectual disability-epilepsy syndrome10.4PTCH1, SHH
28bladder cancer, somatic10.4FGFR2, FGFR3
29intracranial abscess10.4MLH1, MSH6
30poland syndrome10.3FGFR2, FGFR3, MSX2
31qazi markouizos syndrome10.3MLH1, MSH2, MSH6, PMS2, PTCH1
32mismatch repair cancer syndrome10.3MLH1, MSH2, MSH6, PAX3, PMS2
33x-linked intellectual disability, hedera type10.3PTCH1, SHH
34bone deterioration disease10.3FGFR2, FGFR3, MSX2
35craniosynostosis, type 110.3FGFR2, FGFR3, MSX2
36bardet-biedl syndrome10.3ALX4, FGFR2, FGFR3
37tenosynovitis of foot and ankle10.3EPCAM, MLH1, MSH2, MSH6, PMS2
38botulism10.3FGFR2, FGFR3, MSX2
39critical limb ischemia10.3ALX4, FGFR2, FGFR3, MSX2
40hypogonadotropic hypogonadism 2 with or without anosmia10.2FGFR2, FGFR3
41glucocorticoid resistance10.1
42placental insufficiency10.1EPCAM, MLH1, MLH3, MSH2, MSH6, PMS2
43cyclotropia10.1FGFR2, FGFR3
44muscular dystrophy-dystroglycanopathy , type a, 210.1FGFR2, MLH1, MLH3, MSH2, MSH6, PMS2
45basal cell nevus syndrome10.0
46popliteal pterygium syndrome 110.0
47colorectal cancer, hereditary nonpolyposis, type 810.0
48colorectal cancer, hereditary nonpolyposis, type 510.0
49fibrodysplasia ossificans progressiva10.0
50erythermalgia, primary10.0

Graphical network of the top 20 diseases related to Autosomal Dominant Disease:



Diseases related to autosomal dominant disease

Symptoms for Autosomal Dominant Disease

About this section

Drugs & Therapeutics for Autosomal Dominant Disease

About this section

Drugs for Autosomal Dominant Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 192)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Miconazoleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
2
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
3
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
4
Methylphenidateapproved, investigationalPhase 4364113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
 
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate Hydrochloride
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Quillivant XR
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
5
DopamineapprovedPhase 4, Phase 3, Phase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
6
CandesartanapprovedPhase 4, Phase 2149139481-59-72541
Synonyms:
139481-59-7
2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-(P-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl]}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid
2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid
2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid
2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole
AC-203
AC1L1DWT
Amias
Atacand
Atacand, Blopress, Amias, Ratacand,Candesartan
BIDD:GT0350
Blopress
Blopress (TN)
C07468
C081643
C24H20N6O3
CHEBI:216848
CHEBI:3347
 
CHEMBL1016
CID2541
CV 11974
CV-11974
CV11974
Candesartan
Candesartan (USAN/INN)
Candesartan Cilexetil
Candesartan [BAN]
Candesartan [USAN:INN]
Candesartan cilexetil
D00522
DB00796
FT-0083585
HMS2089M22
HSDB 7520
I01-0374
KS-5003
L000156
LS-32740
MolPort-003-845-570
MolPort-005-943-739
NCGC00167474-01
Ratacand
S1578_Selleck
TL8000897
UNII-S8Q36MD2XX
candesartan
7Analgesics, Non-NarcoticPhase 4, Phase 25184
8Anti-Inflammatory AgentsPhase 4, Phase 28478
9AnalgesicsPhase 4, Phase 29358
10Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 23549
11Dopamine Uptake InhibitorsPhase 4925
12Neurotransmitter Uptake InhibitorsPhase 4, Phase 32857
13Angiotensin II Type 1 Receptor BlockersPhase 4, Phase 3949
14calcium channel blockersPhase 4, Phase 3, Phase 21743
15Calcium, DietaryPhase 4, Phase 3, Phase 24678
16Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 19140
17AngiotensinogenPhase 4, Phase 3, Phase 21032
18Angiotensin Receptor AntagonistsPhase 4, Phase 31039
19
Angiotensin IIPhase 4, Phase 3, Phase 2103368521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
20Dopamine AgentsPhase 4, Phase 3, Phase 23084
21Antirheumatic AgentsPhase 4, Phase 28496
22Angiotensin-Converting Enzyme InhibitorsPhase 4, Phase 3, Phase 2634
23Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 118483
24Adrenergic AgentsPhase 4, Phase 34204
25Adrenergic AntagonistsPhase 41253
26Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 117220
27Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13015
28Central Nervous System StimulantsPhase 41721
29Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 15971
30Adrenergic beta-1 Receptor AntagonistsPhase 4292
31Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 110422
32Antihypertensive AgentsPhase 4, Phase 3, Phase 23618
33CeliprololPhase 42
34Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 218510
35Anti-Arrhythmia AgentsPhase 42371
36Adrenergic beta-AntagonistsPhase 4979
37Neurotransmitter AgentsPhase 4, Phase 2, Phase 314795
38Vasodilator AgentsPhase 4, Phase 22926
39
CilnidipinePhase 4, Phase 28132203-70-45282138
Synonyms:
(+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester
132203-70-4
2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
AC-270
AC1NQZJB
Atelec
Atelec (TN)
BRD-A07875874-001-01-6
Bio-0164
C1493_SIGMA
C27H28N2O7
CHEBI:31399
CHEBI:438069
CHEMBL452076
CID5282138
 
Cilnidipine (JAN/INN)
Cilnidipine [INN]
Cinaldipine
Cinalong
D01173
FRC 8653
FRC-8653
HMS2089J07
I06-0491
LS-131293
MolPort-003-845-950
NCGC00162150-01
NCGC00162150-02
NCGC00162150-03
S1293_Selleck
STK623341
Siscard
cilnidipine
40
Candesartan cilexetilPhase 4, Phase 2149145040-37-52540
Synonyms:
(+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)
1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
145040-37-5
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe
AC-204
AC1L1DWQ
ATACAND HCT
Almirall brand of candesartan cilexetil
Amias
Astra brand of candesartan cilexetil
AstraZeneca brand of candesartan cilexetil
Atacand
Atacand (TN)
BRD-A65671304-001-02-6
BSPBio_002691
C07709
C077793
C33H34N6O6
CHEBI:216349
CHEMBL1014
CID2540
Candesartan cilexetil
Candesartan cilexetil (JAN/USAN)
Candesartan cilexetil [USAN]
Candesartan hexetil
D00626
FT-0082579
H212/91
 
HMS1922J09
HMS2093E20
I06-0090
KBio2_002187
KBio2_004755
KBio2_007323
KBio3_001911
KBioGR_001607
KBioSS_002187
Kenzen
L006257
LS-32741
MolPort-003-666-552
NCGC00095123-01
NCGC00095123-02
NCGC00095123-03
Parapres
Promed brand of candesartan cilexetil
Racanda
SPBio_000349
SPECTRUM1504261
ST51052687
Spectrum2_000485
Spectrum3_000996
Spectrum4_001124
Spectrum5_001462
Spectrum_001707
TCV 116
TCV-116
TL8000995
Takeda brand of candesartan cilexetil
UNII-R85M2X0D68
candesartan cilexitil
41
CurcuminPhase 4124458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
42Adrenergic alpha-AntagonistsPhase 4586
43
HydrochlorothiazideapprovedPhase 338758-93-53639
Synonyms:
125727-50-6
3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi
3,4-Dihydrochlorothiazide
58-93-5
6-Chloro-7-sulfamoyl-3, 4-dihy
8049-49-8
AB00052012
AC-11072
AC1L1GDT
AC1Q55FM
AF-614/30832002
AKOS000121373
ARONIS24316
Acesistem
Acuilix
Acuretic
Aldactazide
Aldactazide 25/25
Aldazida
Aldectazide 50/50
Aldoril
Ambap58-93-5
Apo-Hydro
Apresazide
Aquarills
Aquarius
Aquazide H
Aquazide-H
BAS 00371709
BIDD:GT0153
BPBio1_000019
BRD-K13078532-001-05-2
BRN 0625101
BSPBio_000017
BSPBio_002132
Bio-0714
Bremil
Briazide
C7H8ClN3O4S2
CAS-58-93-5
CCRIS 2082
CHEMBL435
CID3639
CPD000035778
Caplaril
Capozide
Carozide
Catiazida
Chlorizide
Chlorosulthiadil
Chlorothiazide
Chlorsulfonamidodihydrobenzothiadiazine dioxide
Chlorzide
Chlothia
Cidrex
Clorana
Component of Butizide Prestabs
Concor Plus
Condiuren
D00340
D006852
DB00999
Diaqua
Dichlorosal
Dichlorotride
Dichlothiazide
Dichlotiazid
Dichlotride
Diclotride
Dicyclotride
Didral
Dihydran
Dihydrochlorothiazid
Dihydrochlorothiazide
Dihydrochlorothiazidum
Dihydrochlorurit
Dihydrochlorurite
Dihydroxychlorothiazidum
Direma
Disalunil
Disothiazid
Diu 25 Vigt
Diu-Melusin
Diu-melusin
Diuril
Diurogen
DivK1c_000289
Dixidrasi
Drenol
Dyazide
EINECS 200-403-3
EU-0100614
Esidrex
Esidrix
Esidrix (TN)
Esimil
Esoidrina
FT-0082750
Fluvin
H 4759
H1274
H2910_SIAL
H4759_SIAL
HCT
HCT-Isis
HCTZ
HCZ
HMS1568A19
HMS1920D19
HMS2091L05
HMS500O11
HMS553N04
HSDB 3096
Hidril
Hidro-Niagrin
Hidrochlortiazid
Hidroclorotiazida
Hidroclorotiazida [INN-Spanish]
Hidroronol
Hidrosaluretil
Hidrotiazida
Hyclosid
Hydrex-semi
Hydril
Hydro Par
Hydro-Aquil
Hydro-D
Hydro-Diuril
Hydro-Saluric
Hydro-T
Hydro-chlor
HydroDIURIL
Hydrochlorat
Hydrochloro Thiazide
Hydrochlorot
Hydrochlorothiazid
Hydrochlorothiazide
Hydrochlorothiazide (JP15/USP/INN)
Hydrochlorothiazide Intensol
Hydrochlorothiazide [INN:BAN:JAN]
 
Hydrochlorothiazidum
Hydrochlorothiazidum [INN-Latin]
Hydrochlorthiazide
Hydrochlorthiazidum
Hydrocot
Hydrodiuretic
Hydrodiuril
Hydropres
Hydrosaluric
Hydrothide
Hydrozide
Hydrozide Injection, Veterinary
Hypothiazid
Hypothiazide
Hytrid
Hyzaar
I09-0531
IDI1_000289
Idroclorotiazide
Idroclorotiazide [DCIT]
Idrotiazide
Inderide
Inderide 80/25
Indroclor
Ivaugan
Jen-Diril
KBio1_000289
KBio2_001357
KBio2_003925
KBio2_006493
KBio3_001352
KBioGR_000351
KBioSS_001357
LS-243
Lopac-H-4759
Lopac0_000614
Lopressor HCT
Lotensin HCT
Lotensin Hct
MLS000069619
Manuril
Maschitt
Maxzide
Maybridge Compound 10
Maybridge1_004336
Mazide 25 mg
Medozide
Megadiuril
Microzide
Microzide (TN)
Mictrin
Mikorten
Modurcen
Moduretic
MolPort-000-144-465
NCGC00015508-01
NCGC00015508-02
NCGC00015508-03
NCGC00015508-07
NCGC00015508-12
NCGC00021906-03
NCGC00021906-04
NCGC00021906-05
NCGC00021906-06
NCGC00021906-07
NCGC00021906-08
NCI-C55925
NCI60_004317
NINDS_000289
NSC 53477
NSC53477
Natrinax
Nefrix
Nefrol
Neo-Codema
Neo-Flumen
Neo-Minzil
Neo-codema
Neoflumen
Newtolide
Novodiurex
Oprea1_357174
Oretic
Pantemon
Panurin
Prestwick0_000009
Prestwick1_000009
Prestwick2_000009
Prestwick3_000009
Prestwick_263
Prinzide
Raunova Plus
Ro-Hydrazide
Ro-hydrazide
Roxane
S1708_Selleck
SAM002554901
SMR000035778
SPBio_001259
SPBio_001938
SPECTRUM1500335
STK315354
Saldiuril
Sectrazide
Selozide
Ser-Ap-Es
Servithiazid
Spectrum2_001040
Spectrum3_000456
Spectrum4_000006
Spectrum5_000824
Spectrum_000877
Spironazide
Su 5879
Tandiur
Thiaretic
Thiuretic
Thlaretic
Timolide
UNII-0J48LPH2TH
Unazid
Unipres
Urodiazin
Urozide
Vaseretic
Vetidrex
WLN: T66 BSWM EM DHJ HG ISZW
ZINC00896569
Ziac
Zide
adiazine-1,1-dioxide
component of Aldactazide
component of Aldoril
component of Caplaril
component of Cyclex
component of Dyazide
component of Esimil
diclot ride
dro-2H-1,2,4-benzothiadiazine 1,1-dioxide
hydrochlorothiazide
panurin dichloride
44
MinoxidilapprovedPhase 33338304-91-54201
Synonyms:
16317-69-4
2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine
2,4-Diamino-6-piperidinilpirimidina-3-ossido
2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]
2,4-Diamino-6-piperidino-pyrimidine-3-oxide
2,4-Diamino-6-piperidinopyrimidine 3-N-oxide
2,4-Diamino-6-piperidinopyrimidine 3-oxide
2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide
2,6-Diamino-4-piperidinopyrimidin-1-oxid
3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine
3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
38304-91-5
5-25-12-00317 (Beilstein Handbook Reference)
6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide
6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide
6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine
6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide
6-Piperidino-2,4-diaminopyrimidine 3-oxide
6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide
AB00513797
AC-5271
AC1L1HN1
Alopexil
Alostil
Ambap38304-91-5
Apo-Gain
Apo-gain
BCBcMAP01_000193
BPBio1_000065
BRD-K06902185-001-05-2
BRD-K14888893-001-02-3
BRN 0886240
BSPBio_000059
BSPBio_001385
BSPBio_002037
Bio1_000084
Bio1_000573
Bio1_001062
Bio2_000105
Bio2_000585
Boost Regrowth For Women
Bosley Professional Strength Hair Regrowth Treatment Regular Strength For Men
Bosley Professional Strength Hair Regrowth Treatment Regular Strength For Women
C9H15N5.H2O
CAS-38304-91-5
CBiol_001798
CHEBI:49774
CHEBI:6942
CHEMBL609587
CHEMBL802
CID4201
CPD-7668
CPD000058963
Careone Hair Regrowth Treatment
Careone Hair Regrowth Treatment Extra Strength
Cerafill Retaliate
Cerafill Retaliate Extra Strength For Men
D00418
D008914
DB00350
DB08225
DivK1c_000160
EINECS 253-874-2
EU-0100786
Equaline Hair Regrowth Treatment For Men
Equaline Hair Regrowth Treatment For Women
Equaline Hair Regrowth Treatment for men
Equaline Hair Regrowth Treatment for women
Equate Hair Regrowth Treatment
Equate Hair Regrowth Treatment for men
Equate Hair Regrowth Treatment for women
Gen-Minoxidil
Good Neighbor Pharmacy Hair Regrowth Treatment For Men
Good Sense Hair Regrowth Treatment
Good Sense Hair Regrowth Treatment for Men
Good Sense Hair Regrowth Treatment for women
HMS1361F07
HMS1568C21
HMS1791F07
HMS1920P03
HMS1989F07
HMS2089L08
HMS2091F20
HMS500H22
HSDB 6538
Hair Regrowth Treatment
Hair Regrowth Treatment Extra Strength for Men
Hair Regrowth Treatment For Men
Hair Regrowth Treatment For Men Extra Strength
Hair Regrowth Treatment For Women
Hair Regrowth Treatment for women
Hair Regrowth treatment for men
Hair Regrowth treatment for women
Harmon Face Values Minoxidil
IDI1_000160
IDI1_033855
Image Essentials Hair Regrowth Treatment
Image Essentials Hair Regrowth Treatment For Men
Jsp006715
KBio1_000160
KBio2_000105
KBio2_001449
KBio2_002673
KBio2_004017
KBio2_005241
KBio2_006585
KBio3_000209
KBio3_000210
KBio3_001537
KBioGR_000105
KBioGR_000585
KBioSS_000105
KBioSS_001449
Keranique For Women Hair Regrowth Treatment
Kirkland Signature Minoxidil
LS-135040
Leader Hair Regrowth Treatment
Loesch Hair Regrowth Formula Unscented Topical Solution Extra-Strength for Men
 
Loniten
Loniten (TN)
Lonolox
Lopac-M-4145
Lopac0_000786
M 4145
M1389
MINOXIDIL (FOR MEN)
MINOXIDIL (FOR WOMEN)
MINOXIDIL EXTRA STRENGTH (FOR MEN)
MINOXIDIL EXTRA STRENGTH FOR MEN
MLS000028566
MLS000859953
MLS001077294
Men s Rogaine Foam
Men's Rogaine
Mens Comback Hair Regrowth Treatment Extra Strength Unscented
Mens Hair Regrowth Treatment extra strength
Mens Kirkland Extra Strength
Mens Rogaine Extra Strength
Mens Rogaine Foam
Mens Rogaine Unscented Formula
Minodyl
Minossidile
Minossidile [Italian]
Minoxidil
Minoxidil (USP/INN)
Minoxidil Foam
Minoxidil For Women
Minoxidil Form Men extra strength
Minoxidil Pfizer Brand
Minoxidil [USAN:BAN:INN]
Minoxidil for men
Minoxidil for women
Minoxidil regular strength
Minoxidilum
Minoxidilum [INN-Latin]
Minoxigaine
Minoximen
MolPort-003-666-236
MolPort-005-932-694
NCGC00015673-01
NCGC00015673-02
NCGC00015673-04
NCGC00015673-11
NCGC00018278-01
NCGC00024666-01
NCGC00024666-02
NCGC00024666-03
NCGC00024666-04
NCGC00024666-05
NCGC00024666-06
NCGC00024666-07
NCGC00024666-08
NCGC00179672-01
NINDS_000160
Neoxidil
Nioxin Hair Regrowth Treatment Extra Strength For Men
Nioxin Hair Regrowth Treatment For Women
Normoxidil
Pantene Pro-v Expert Collection Hair Regrowth Treatment for Women
Pfizer Brand of Minoxidil
Pierminox
Prestwick0_000020
Prestwick1_000020
Prestwick2_000020
Prestwick3_000020
Prestwick_521
Prexidil
Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide
ROGAINE (FOR MEN)
ROGAINE (FOR WOMEN)
ROGAINE EXTRA STRENGTH (FOR MEN)
Re-gro
Regaine
Renewal For Men
RiUP
Riup (TN)
Rogaine
Rogaine (TN)
Rogaine Extra Strength for Men
Rogaine for Men
Rogaine for Women
Rogaine, Regaine, Avacor and Mintop, Minoxidil
S1383_Selleck
SAM002589949
SBB056986
SGCUT00112
SMP1_000192
SMR000058963
SMR000326812
SPBio_001006
SPBio_001980
SPECTRUM1500415
Simply Right Minoxidil
Simply Right Minoxidil extra strength
Solution
Spectrum2_001053
Spectrum3_000509
Spectrum4_000063
Spectrum5_001299
Spectrum_000969
TM-160
Theroxidil
Tocris-0583
Toppik Mens Hair Regrowth Treatment Extra Strength
Toppik Womens Hair Regrowth Treatment
Tricoxidil
Trocoxidil
U 10858
U-10,858
U-10858
Vanarex Hair Regrowth Treatment
Womens Rogaine - Unscented
Womens Rogaine Unscented
ZINC00001735
minoxidil
nchembio.79-comp10
to_000070
45
MipomersenapprovedPhase 3, Phase 2161000120-98-8, 629167-92-6
Synonyms:
ISIS-301012
 
Kynamro
Mipomersen
Mipomersen sodium
46
Metoprololapproved, investigationalPhase 319337350-58-64171
Synonyms:
(+/-)-Metoprolol
(RS)-Metoprolol
1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol
1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol
1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol
3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol
37350-58-6
51384-51-1
54163-88-1
AB00053499
AC-19022
AC1L1HKM
AstraZeneca Brand of Metaoprolol Tartrate
AstraZeneca Brand of Seloken
BRD-A03623303-045-02-0
Beatrolol
Beloc
Beloc Duriles
Beloc-Duriles
BelocDuriles
Betaloc
Betaloc Astra
Betaloc-Astra
BetalocAstra
Betalok
C07202
CCRIS 4198
CGP 2175
CGP-2175
CGP2175
CHEBI:6904
CHEMBL13
CID4171
D008790
D02358
DB00264
Dl-Metoprolol
Dutoprol
EINECS 253-483-7
EINECS 257-166-4
H 93 26
H 93-26
H 9326
HMS2090B15
 
HSDB 6531
I01-7125
I06-0125
Jsp006606
L000669
LOPRESSIDONE
LS-122450
Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate
Lopresor
Lopresoretic
Lopressor
Lopressor HCT
Meijoprolol
Metohexal
Metoprolol
Metoprolol (USAN/INN)
Metoprolol Succinate
Metoprolol Succinate extended-release
Metoprolol Tartrate
Metoprolol [USAN:INN:BAN]
Metoprolol succinate
Metoprolol tartrate
Metoprololum
Metoprololum [INN-Latin]
Metroprolol
MolPort-005-938-039
NCGC00021148-02
NCGC00021148-03
NCGC00021148-04
Novartis Brand of Metprolol Tartrate
Preblok
Prelis
Presolol
Selo-Zok
Seloken
Seloken AstraZeneca Brand
Selopral
Seroken
Spesicor
Spesikor
TOPROL-XL
Tartrate, Metoprolol
Toprol
Toprol XL
Toprol-XL
UNII-GEB06NHM23
dl-Metoprolol
metoprolol
47
HydralazineapprovedPhase 34286-54-43637
Synonyms:
(1Z)-1(2H)-Phthalazinone hydrazone
(2H)-Phthalazinone hydrazone
1(2H)-Phthalazinone hydrazone
1(2H)-Phthalazinone, hydrazone
1-Hydrazinophthalazine
1-Phthalazinylhydrazine
304-20-1 (mono-hydrochloride)
5-25-17-00412 (Beilstein Handbook Reference)
6-Hydralazine
86-54-4
AC1L1GDN
AC1Q4UY1
AKOS000122609
Apresolin
Apresoline
Apressin
Apressin (pharmaceutical)
Apressoline
Aprezolin
BA 5968
BRD-K82103381-003-03-7
BRN 0132615
BSPBio_002130
C 5968
C-5068
C-5968
C07040
C8H8N4
CAS-304-20-1
CCRIS 5385
CHEBI:5775
CHEMBL276832
CID3637
Ciba 5968
D08044
DB01275
DivK1c_000117
EC-000.1838
EINECS 201-680-3
HLZ
Hidral
Hidral (TN)
Hidralazin
Hidralazina
Hidralazina [INN-Spanish]
Hidralazina [Spanish]
Hipoftalin
Hydralazin
Hydralazine
Hydralazine (INN)
Hydralazine Hydrochloride
Hydralazine [INN:BAN]
 
Hydralazine hydrochloride
Hydralazinum
Hydralazinum [INN-Latin]
Hydrallazin
Hydrallazine
Hydrazinophthalazine
Hydrazone 1(2H)-phthalazinone
Hypophthalin
IDI1_000117
Idralazina
Idralazina [DCIT]
Idralazina [Italian]
InChI=1/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
KBio1_000117
KBio2_001355
KBio2_003923
KBio2_006491
KBio3_001350
KBioGR_000349
KBioSS_001355
LS-109171
Lopac-H-1753
Lopac0_000593
MolPort-000-876-738
MolPort-001-794-088
NCGC00015501-01
NCGC00015501-02
NCGC00015501-05
NCGC00162199-01
NCIOpen2_001484
NINDS_000117
NSC 126699
NSC126699
Oprea1_207681
Oprea1_416878
Phthalazin-1-ylhydrazine
Praparat 5968
Prestwick0_000169
Prestwick1_000169
Prestwick2_000169
SPBio_000977
SPBio_001958
ST50512087
Spectrum2_000969
Spectrum3_000455
Spectrum4_000005
Spectrum5_000822
Spectrum_000875
UNII-26NAK24LS8
WLN: T66 CNNJ BMZ
ZINC12360535
[2H-Phthalazin-(1Z)-Ylidene]-Hydrazine Hydrochloride
hydralazine
phthalazin-1-ylhydrazine
48
Octreotideapproved, investigationalPhase 3, Phase 219883150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
 
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Ocphyl
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatin
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
49
DiltiazemapprovedPhase 37042399-41-739186
Synonyms:
(+)-cis-5-[2-(dimethylamino)Ethyl]-2,3-dihydro-3-hydroxy-2-(P-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester
(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester
(2S,3S)-5-(2-(dimethylamino)Ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
(2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate
(2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate
(2S-cis)-3-(Acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
(2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
144604-00-2
33286-22-5
42399-41-7
AC-936
AC1L2181
AC1Q6LHX
Acalix
Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester
Adizem
Aldizem
Altiazem
Anginyl
Angizem
Anoheal
Apo-Diltiaz
BIDD:GT0548
BPBio1_000230
BRD-K24023109-001-02-5
BRD-K24023109-003-03-9
BRN 3573079
BSPBio_000208
BSPBio_001311
Bio1_000371
Bio1_000860
Bio1_001349
Britiazim
Bruzem
C06958
C22H26N2O4S
CHEBI:101278
CHEMBL23
CID39186
Calcicard
Cardil
Cardizem
Cardizem (Hydrochloride)
Cardizem CD
Cardizem SR
Cardizen LA
Cartia XT
Citizem
Cormax
D-cis-Diltiazem
D07845
DB00343
Deltazen
Dilacor
Dilacor-XR
Diladel
Dilcontin
Dilpral
 
Dilren
Dilrene
Dilt-cd
Dilta-Hexal
Diltia
Diltiazem
Diltiazem (INN)
Diltiazem Hydrochloride
Diltiazem [INN:BAN]
Diltiazem hydrochloride
Diltiazemum
Diltiazemum [INN-Latin]
Dilticard
Diltzac
Dilzem
Dilzen
EINECS 255-796-4
Endrydil
FT-0081415
HMS1791B13
HMS1989B13
HMS2089H09
HSDB 6528
Herbesser
Incoril AP
LS-40510
Lopac0_000327
MK-793 (Malate)
Masdil
MolPort-002-509-369
NCGC00024309-02
NCGC00024309-04
NCGC00024309-05
NCGC00024309-06
NCGC00024309-07
NCGC00024309-08
NCGC00024309-09
NCGC00024309-10
Novo-Diltazem
Nu-Diltiaz
Prestwick0_000134
Prestwick1_000134
Prestwick2_000134
Prestwick3_000134
RG 83606 (Hydrochloride)
SPBio_002147
STOCK1N-03672
Surazem (TN)
Syn-Diltiazem
Tiamate
Tiazac
Tiazac Tildiem
Tiazac XC
Tocris-0685
UNII-EE92BBP03H
Viazem
[(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
d-cis-Diltiazem
diltiazem
nchembio.368-comp1
50
Lisinoprilapproved, investigationalPhase 311683915-83-75362119
Synonyms:
(2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
(S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
1-[Nalpha-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline
76547-98-3
77726-95-5
83915-83-7 (Parent)
AC1NSFPF
Acerbon
Acercomp
Alapril
BB_NC-1454
BIDD:GT0755
BPBio1_000290
BRD-K67966701-335-03-5
BRN 4276619
BSPBio_000262
C21H31N3O5
CCRIS 3568
CHEBI:43755
CHEMBL1237
CID5362119
Carace
Cipral
Cipril
Coric
D08131
DB00722
DivK1c_001037
Doneka
EINECS 278-488-1
HMS1921B14
HMS2090O14
HMS2092L21
HMS503O15
I06-1895
ICI-209K
IDI1_001037
Inhibril
Inopril
KBio1_001037
KBio2_000977
KBio2_003545
KBio2_006113
KBio3_002002
KBioGR_001599
KBioSS_000977
L0220
LPR
LS-118899
Linopril
Linvas
Lipril
Lisinal
Lisinopril
Lisinopril (INN)
 
Lisinopril (anhydrous)
Lisinopril 10mg
Lisinopril 2.5mg
Lisinopril 20mg
Lisinopril 40mg
Lisinopril 5mg
Lisinopril Dihydrate
Lisinopril anhydrous
Lisinoprilum
Lisinoprilum [Latin]
Lisipril
Lisoril
Lispril
Longes
Loril
Lysinopril
MK 521
MK 522
MK-521
MLS001306436
MLS001306481
MolPort-002-507-428
N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline
N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl-L-proline
N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
NCGC00179623-01
NINDS_001037
Noperten
Novatec
Presiten
Prestwick0_000301
Prestwick1_000301
Prestwick2_000301
Prestwick3_000301
Prinil
Prinivil
Prinzide
Renacor
SMR000544473
SPBio_001351
SPBio_002481
SPECTRUM1501217
Sinopril
Sinopryl
Spectrum2_001456
Spectrum3_000941
Spectrum4_001040
Spectrum5_000995
Spectrum_000497
TL8005499
Tensopril
Tensyn
Tersif
Vivatec
Zestoretic
Zestril
Zestril (TN)
[N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE
[N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
lisinopril

Interventional clinical trials:

(show top 50)    (show all 191)
idNameStatusNCT IDPhase
1Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00414440Phase 4
2PROTECT Continued Access Post Marketing Surveillance TrialCompletedNCT00846846Phase 4
3Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular TypeCompletedNCT00190411Phase 4
4NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by MethylphenidateCompletedNCT00169611Phase 4
5Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKDRecruitingNCT02494141Phase 4
6CCB Safety Study in Treatment of Hypertension of ADPKDNot yet recruitingNCT00541853Phase 4
7Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00456365Phase 3
8Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00346918Phase 3
9Open-Label Tolvaptan Study in Subjects With ADPKDCompletedNCT01214421Phase 3
10A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]CompletedNCT01022424Phase 3
11A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]CompletedNCT01280721Phase 3
12Tolvaptan Phase 3 Efficacy and Safety Study in ADPKDCompletedNCT00428948Phase 3
13Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyCompletedNCT00309283Phase 3
14Effects of Somatostatin on Liver in ADPKDCompletedNCT02119052Phase 2, Phase 3
15Effects of Somatostatin on ADPKD HeartCompletedNCT02119013Phase 2, Phase 3
16Lanreotide as Treatment of Polycystic LiversCompletedNCT00565097Phase 2, Phase 3
17Octreotide in Severe Polycystic Liver DiseaseCompletedNCT00426153Phase 2, Phase 3
18Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT00685373Phase 3
19Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT01576367Phase 3
20Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension PhaseCompletedNCT00991146Phase 3
21Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT01302860Phase 3
22HALT Progression of Polycystic Kidney Disease (HALT PKD) Study BCompletedNCT01885559Phase 3
23HALT Progression of Polycystic Kidney Disease (HALT PKD) Study ACompletedNCT00283686Phase 3
24Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells SyndromeCompletedNCT00465985Phase 3
25An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-HypercholesterolemiaCompletedNCT00694109Phase 3
26Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial HypercholesterolemiaCompletedNCT00607373Phase 3
27Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3CompletedNCT01096082Phase 2, Phase 3
28Efficacy of Riluzole in Hereditary Cerebellar AtaxiaCompletedNCT01104649Phase 2, Phase 3
29Efficacy and Safety of Tolvaptan in Cirrhotic Patients With HyponatremiaCompletedNCT01850940Phase 3
30Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT02055079Phase 3
31The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted RecipientsRecruitingNCT02134899Phase 3
32Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingNCT02115659Phase 3
33Lanreotide In Polycystic Kidney Disease StudyRecruitingNCT02127437Phase 3
34Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and TiaprideRecruitingNCT00632645Phase 3
35Sirolimus for Massive Polycystic LiverRecruitingNCT01680250Phase 2, Phase 3
36Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT02160145Phase 3
37Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal InsufficiencyActive, not recruitingNCT01377246Phase 3
38Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT02225860Phase 2, Phase 3
39Study of Lanreotide to Treat Polycystic Kidney DiseaseActive, not recruitingNCT01616927Phase 3
40Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.Active, not recruitingNCT01760005Phase 2, Phase 3
41Open-Label Extension of LOCKCYST TrialActive, not recruitingNCT00771888Phase 2, Phase 3
42Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseEnrolling by invitationNCT02251275Phase 3
43Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial DiseaseEnrolling by invitationNCT02023866Phase 2, Phase 3
44Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyTerminatedNCT01223755Phase 2, Phase 3
45Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to TherapyTerminatedNCT00920309Phase 2, Phase 3
46PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE InhibitorsTerminatedNCT01583114Phase 3
47Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)TerminatedNCT02106520Phase 2, Phase 3
48Bosutinib For Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01233869Phase 2
498-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01451827Phase 2
50Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00286156Phase 1, Phase 2

Search NIH Clinical Center for Autosomal Dominant Disease

Genetic Tests for Autosomal Dominant Disease

About this section

Anatomical Context for Autosomal Dominant Disease

About this section

MalaCards organs/tissues related to Autosomal Dominant Disease:

33
Kidney, Liver, Bone, Endothelial, Heart, Lung, Skin

Animal Models for Autosomal Dominant Disease or affiliated genes

About this section

MGI Mouse Phenotypes related to Autosomal Dominant Disease:

38 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.6FGFR2, FGFR3, GJB2, MSX2, PAX3, SHH
2MP:00053889.6ALX4, FGFR2, FGFR3, PAX3, PTCH1, RUNX1
3MP:00030129.5EPCAM, FGFR2, FGFR3, GJB2, PAX3, PTCH1
4MP:00053719.4ALX4, FGFR2, FGFR3, GJB2, MSX2, PAX3
5MP:00053699.3ALX4, FGFR2, HMBS, MSX2, PAX3, PTCH1
6MP:00053829.3ALX4, FGFR2, FGFR3, GJB2, MSX2, PAX3
7MP:00053919.3ALX4, FGFR2, FGFR3, GJB2, MLH1, MSX2
8MP:00020069.3FGFR2, FGFR3, MLH1, MSH2, MSH6, PAX3
9MP:00053809.1ALX4, DLX3, EPCAM, FGFR2, GJB2, MSX2
10MP:00028739.0ALX4, FGFR2, FGFR3, GJB2, HMBS, MSX2
11MP:00053819.0ALX4, EPCAM, FGFR2, FGFR3, MLH1, MSH2
12MP:00053799.0DLX3, EPCAM, FGFR2, MLH1, MLH3, MSX2
13MP:00053858.7DLX3, EPCAM, FGFR2, GJB2, MSX2, PAX3
14MP:00053908.6ALX4, FGFR2, FGFR3, GJB2, MSX2, PAX3
15MP:00053868.6ALX4, EPCAM, FGFR2, FGFR3, HMBS, MLH1
16MP:00107718.6ALX4, DLX3, FGFR2, FGFR3, GJB2, MLH1
17MP:00053978.6EPCAM, FGFR2, FGFR3, MSH2, MSX2, PAX3
18MP:00053768.5EPCAM, FGFR2, FGFR3, GJB2, HMBS, MLH1
19MP:00053848.5EPCAM, FGFR2, FGFR3, GJB2, MLH1, MSH2
20MP:00053788.4ALX4, DLX3, EPCAM, FGFR2, FGFR3, GJB2
21MP:00036318.4ALX4, EPCAM, FGFR2, FGFR3, GJB2, HMBS
22MP:00053878.4EPCAM, FGFR2, FGFR3, GJB2, MSH2, MSX2
23MP:00107687.7ALX4, DLX3, EPCAM, FGFR2, FGFR3, GJB2

Publications for Autosomal Dominant Disease

About this section

Articles related to Autosomal Dominant Disease:

idTitleAuthorsYear
1
SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase. (23970103)
2013
2
Recovery of cognitive functioning in patients with co-occurring bipolar disorder and alcohol dependence during early remission from an acute mood episode. (22563570)
2012
3
Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. (21285249)
2011
4
Mechanism of regulation of Na-H exchanger in inflammatory bowel disease: role of TLR-4 signaling mechanism. (21221801)
2011
5
Exogenous expression of Esophagin/SPRR3 attenuates the tumorigenicity of esophageal squamous cell carcinoma cells via promoting apoptosis. (17935133)
2008
6
Copy number polymorphisms are not a common feature of innate immune genes. (16617005)
2006
7
An in vitro study on radiation-induced TNF gene therapy of cancer]. (9387244)
1996

Variations for Autosomal Dominant Disease

About this section

Expression for genes affiliated with Autosomal Dominant Disease

About this section
Search GEO for disease gene expression data for Autosomal Dominant Disease.

Pathways for genes affiliated with Autosomal Dominant Disease

About this section

GO Terms for genes affiliated with Autosomal Dominant Disease

About this section

Cellular components related to Autosomal Dominant Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1chiasmaGO:000571210.2MLH1, MLH3

Biological processes related to Autosomal Dominant Disease according to GeneCards Suite gene sharing:

(show all 28)
idNameGO IDScoreTop Affiliating Genes
1somatic recombination of immunoglobulin genes involved in immune responseGO:000220410.9MLH1, MSH2
2somatic recombination of immunoglobulin gene segmentsGO:001644710.9MLH1, MSH2
3negative regulation of DNA recombinationGO:004591010.8MSH2, MSH6
4prostate epithelial cord elongationGO:006052310.7FGFR2, SHH
5male meiosisGO:000714010.7MLH1, MLH3
6endochondral bone growthGO:000341610.7FGFR3, MSX2
7branching involved in prostate gland morphogenesisGO:006044210.7FGFR2, SHH
8trachea morphogenesisGO:006043910.7SHH, TGFBR2
9patterning of blood vesselsGO:000156910.7SHH, TGFBR2
10somite developmentGO:006105310.6PTCH1, SHH
11lung lobe morphogenesisGO:006046310.6SHH, TGFBR2
12lung-associated mesenchyme developmentGO:006048410.6FGFR2, SHH
13positive regulation of phospholipase activityGO:001051810.6FGFR2, FGFR3
14embryonic digestive tract morphogenesisGO:004855710.6FGFR2, SHH
15limb bud formationGO:006017410.6FGFR2, SHH
16positive regulation of mesenchymal cell proliferationGO:000205310.5FGFR2, TGFBR2
17branching involved in ureteric bud morphogenesisGO:000165810.5PTCH1, SHH
18embryonic organ developmentGO:004856810.4FGFR2, PTCH1, SHH
19embryonic pattern specificationGO:000988010.4FGFR2, SHH
20branching involved in salivary gland morphogenesisGO:006044510.4FGFR2, SHH
21pattern specification processGO:000738910.3ALX4, PTCH1, SHH
22odontogenesisGO:004247610.3FGFR2, MSX2, SHH
23in utero embryonic developmentGO:000170110.2FGFR2, MSH2, PTCH1, TGFBR2
24response to estradiolGO:003235510.0GJB2, HMBS, PTCH1
25bone morphogenesisGO:00603499.9FGFR2, FGFR3, MSX2
26DNA repairGO:00062819.9MLH1, MSH2, MSH6, VCP
27lung developmentGO:00303249.9FGFR2, SHH, TGFBR2
28palate developmentGO:00600219.7ALX4, SHH, TGFBR2

Molecular functions related to Autosomal Dominant Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1guanine/thymine mispair bindingGO:003213710.8MSH2, MSH6
2single thymine insertion bindingGO:003214310.8MSH2, MSH6
3ADP bindingGO:004353110.7MSH2, MSH6
4fibroblast growth factor-activated receptor activityGO:000500710.7FGFR2, FGFR3
5single-stranded DNA bindingGO:00036979.9MLH1, MLH3, MSH2, PMS2
6ATP bindingGO:00055249.4MLH3, MSH2, PMS2, TGFBR2, VCP

Sources for Autosomal Dominant Disease

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet